AU-011

DRUG4 trials

Sponsors

Aura Biosciences

Conditions

Choroidal MelanomaEye CancerIndeterminate LesionsNMIBCNon-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCGNon-Muscle Invasive Bladder CarcinomaNon-Muscle Invasive Bladder NeoplasmsNon-Muscle Invasive Bladder Urothelial Carcinoma

Phase 1

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

RecruitingNCT05483868

Aura BiosciencesNMIBC, Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG +4

Start: 2022-09-26End: 2027-03-31Target: 55Updated: 2025-12-04

Phase 2

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

CompletedNCT04417530

Aura BiosciencesChoroidal Melanoma, Ocular Melanoma, Uveal Melanoma

Start: 2020-08-05End: 2024-04-22Updated: 2025-03-03

Suprachoroidal Administration in Subjects With Metastases to the Choroid

RecruitingNCT06643884

Aura BiosciencesEye Cancer, Primary Cancer

Start: 2024-12-16End: 2027-10-31Target: 24Updated: 2026-03-13

Unknown Phase

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

TerminatedNCT05266430

Aura BiosciencesChoroidal Melanoma, Indeterminate Lesions

Start: 2022-04-14End: 2023-04-20Updated: 2023-08-09

Related Papers

A phase 1, open-label trial to evaluate feasibility and safety of intramural injection of belzupacap sarotalocan (AU-011) in non-muscle–invasive bladder cancer (NMIBC).

Journal of Clinical Oncology2023-02-202 citations